Article

Composite endpoints to detect treatment effects on MS disability progression. Lessons from phase III trial data

2026-04-24

Abstract excerpt

Disability worsening is the critical long-term outcome in multiple sclerosis, yet the Expanded Disability Status Scale incompletely captures neurological deterioration and has limited sensitivity in the short time windows of clinical trials. Composite endpoints incorporating functional measures have been proposed to address these limitations, but whether they reliably improve detection of treatment effects has not...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0686108e-58db-5d68-bcc8-5700bab900c8
DOI: 10.64898/2026.04.22.26351458

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Composite endpoints to detect treatment effects on MS disability progression. Lessons from phase III trial dataDOI 10.64898/2026.04.22.26351458Read

MS functional composite: relation to disease phenotype and disability strata.Semantic proximity Read

Exploring a milestone-based outcome measure for disease-modifying trials in Parkinson’s diseaseSemantic proximity Read

Quantifying MS Progression in the Era of Highly Effective Therapy: Trial Design ImplicationsSemantic proximity Read

Predicting personalised risk of disability worsening in multiple sclerosis with machine learningSemantic proximity Read

Optimal Clinical Trials Platform for Progressive Multiple Sclerosis (OCTOPUS): protocol for an international, multi-arm, multi-stage, platform, randomized controlled, double-blind, phase 3 clinical trialSemantic proximity Read

Phenotypic Diversity in Multiple Sclerosis Can Be Represented by Four Additive Symptom ModulesSemantic proximity Read

Multimodal predictors of disability progression and processing speed decline in relapsing-remitting multiple sclerosisSemantic proximity Read

Differences and Similarities in Clinical and Functional Responses Among Patients Receiving Tofacitinib Monotherapy, Tofacitinib Plus Methotrexate, and Adalimumab Plus Methotrexate: A Post-hoc Analysis of Data From Oral StrategySemantic proximity Read

Ocrelizumab versus Natalizumab in Relapsing-Remitting Multiple Sclerosis: A Registry-Linked Electronic Health Records StudySemantic proximity Read

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.Semantic proximity Read

Biomarker combinations from different modalities predict early disability accumulation in multiple sclerosisSemantic proximity Read

When scalar endpoints cannot identify multidomain stabilization: estimand-aligned trajectory summaries for chronic longitudinal trialsSemantic proximity Read